Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Ference

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
European Heart Journal|August 29, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Atherosclerosis|August 30, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Giornale Italiano Di Cardiologia (2006)|October 27, 2025
[2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias]François Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Atherosclerosis|April 3, 2026
Erratum to "2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias" [Atherosclerosis, 409, (October 2025), 120479]François Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
American Heart Journal|May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYNStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
The New England Journal of Medicine|May 8, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Global Heart|November 16, 2022
World Heart Federation Cholesterol Roadmap 2022Kausik K Ray, Brian A Ference, Tania Séverin, et al.
Atherosclerosis|May 15, 2023
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis SocietyFlorian Kronenberg, Samia Mora, Erik S G Stroes, et al.
European Heart Journal|October 19, 2017
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemiaUlf Landmesser, M John Chapman, Jane K Stock, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
European Heart Journal|August 29, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Atherosclerosis|August 30, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Giornale Italiano Di Cardiologia (2006)|October 27, 2025
[2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias]François Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Atherosclerosis|April 3, 2026
Erratum to "2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias" [Atherosclerosis, 409, (October 2025), 120479]François Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
American Heart Journal|May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYNStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
The New England Journal of Medicine|May 8, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Global Heart|November 16, 2022
World Heart Federation Cholesterol Roadmap 2022Kausik K Ray, Brian A Ference, Tania Séverin, et al.
Atherosclerosis|May 15, 2023
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis SocietyFlorian Kronenberg, Samia Mora, Erik S G Stroes, et al.
European Heart Journal|October 19, 2017
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemiaUlf Landmesser, M John Chapman, Jane K Stock, et al.
Pageof 7